Cencora, Inc.

Hello everyone and thank you for joining the Sancora Fiscal 2025 Third Quarter Results Call. My name is Lucy and I'll be coordinating a call today. During the presentation you can register a question by pressing staff followed by one on your telephone keypad. If you change your mind please press staff followed by two. It is now my pleasure to hand over to your host, Bennett Murphy, Senior Vice President of Investor Relations and Treasury, to begin. Please go ahead.

Thank you. Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Sancora's Fiscal 2025 Third Quarter Results. I am Bennett Murphy, Senior Vice President, Head of Investor Relations and Treasury. Joining me today are Bob Motch, President and CEO, and Jim Cleary, Executive Vice President and CFO. On today's call we will be discussing non-GAAP financial measures. Reconciliation of these measures to GAAP are provided in today's press release which is available on our website at .sancora.com. We have also posted a slide presentation to accompany today's press release on our investor website. During this conference call we will discuss forward-looking statements about our business and financial expectations on an adjusted non-GAAP basis, including but not limited to EPS, operating income, and income taxes. Forward-looking statements are based on our management's current expectations and are subject to uncertainty and change. For our discussion of key risks and assumptions we refer you to today's press release and our SEC filings including our most recent 10Q. Sancora assumes no obligation to update any forward-looking statements and this call cannot be rebroadcast without the express permission of the company. You will have the opportunity to ask questions after today's remarks by management. We ask that you limit your questions to one per participant in order for us to get to as many participants as possible within the hour. With that I will turn the call over to Bob.

Thank you, Bennett. Hi everyone and thank you for joining Sancora's Fiscal 2025 Third Quarter Earnings call. To start, I'd like to thank the over 51,000 Sancora team members for the industry-leading expertise and purpose-driven approach they bring to work each day. Their talent and commitment fuel our growth as we continue to strengthen our position as an -to-end healthcare solutions provider. Through the strength of our strategy, services, and unwavering standards, Sancora's business model is driven by pharmaceutical distribution and complemented by higher margin, high growth, value-added services and solutions for our biopharma and provider customers. In our third quarter, Sancora delivered strong performance with adjusted operating income growth of 21% and adjusted diluted EPS growth of 20%. In recognition of our outperformance during the quarter and -to-date, both in the U.S. segment and on a consolidated basis, we are pleased to once again raise our fiscal 2025 guidance. Today, I will highlight three growth priorities. First, enhancing patient care and adherence. Through decades of investment in physical and digital infrastructure, our core pharmaceutical distribution services ensure access to life-saving medications. Second, strengthening our specialty leadership. As we focus on future growth, we are differentiating the services and solutions we offer to pharmaceutical manufacturers to support specialty product innovation. And third, leading with market leaders. By prioritizing active learning and active leading, we identify opportunities to create value in collaboration with our leading customer portfolio. I'll begin with how Sancora enhances patient access to pharmaceuticals through our critical role as a leader in pharmaceutical distribution. Our global reach, coupled with our local expertise, ensures patients have access to the medications they need, when and where they need them in an efficient, reliable and secure manner. We've invested in our distribution capabilities for decades, enhancing our efficiency, security and ability to handle increasingly complex medications, allowing us to meet the needs of innovation and the increased use of pharmaceuticals. We are responsible for delivering millions of pharmaceutical orders overnight or the same day to hundreds of thousands of healthcare providers we serve, ensuring pharmacists, physicians, veterinarians and other healthcare providers have access to the medications they require to treat patients. Specifically, we believe our investments over the past decade have made Sancora a market leader in ensuring the supply chain is supported and equipped to comply with the enhanced tracking and visibility requirements of the Drug Supply Chain Security Act, DSCSA, which goes into effect later this year in the United States. The significant investments made over the past several years in support of the DSCSA is yet another clear proof point of the vital role Sancora and our industry play to ensure patients efficient, safe and reliable access to medication. Next, Sancora is strengthening our leadership and specialty by enhancing capabilities through RCA. RCA's physician-centric approach in Retina is enhancing clinical trial access, supporting specialty product innovation and improved outcomes for patients. Recently, physician and business leaders across the RCA organization came together at our offices outside Philadelphia for their business and medical leadership board. The time our team spent together demonstrated collective value as we focused on practice management, value creation and the future of patient care. In addition, Retina specialists across RCA had a significant presence at the annual American Society of Retina Specialist Meeting, which was oriented around highlighting the rapid innovation in Retina treatments. RCA physicians drove discussions and clinical research where they demonstrated clinical excellence, strong clinical trial patient enrollments and novel therapeutic approaches, including the delivery of an investigational gene therapy. We are proud to support these groundbreaking clinicians. Additionally, Sancora's long-standing leadership and specialty distribution, including deep relationships in the Retina market, equips us with specific expertise to support manufacturer's product launches. As a result, we look forward to serving as the specialty distributor for several recently approved Retina therapies that are beginning to enter both the U.S. and international markets. Through these partnerships, we are facilitating streamlined market entry, secure storage and distribution. Innovation is driving specialty pharmaceutical market growth, and Sancora is deepening our leadership and specialty by remaining at the forefront through our portfolio of services and solutions -to-end from manufacturers to specialty providers. And finally, our focus on active learning and active leading is bolstering relationships with our industry-leading portfolio of customers, furthering our leadership with market leaders. Our teams are prioritizing focused engagement with our partners to deeply understand their business challenges and growth opportunity. The intentional time we spend with our customers is helping inform how we invest and expand our business to best create value. Throughout the quarter, we drove meaningful interactions with our customers and partners across the supply chain. As an example, we hosted our annual Good Neighbor Pharmacy Thought Spot Conference, giving our independent pharmacy customers the opportunity to learn about the latest trends shaping the industry and connect with peers. Our enterprise leadership team recently had the opportunity to visit a Good Neighbor Pharmacy member that is a great representation of a pharmacy that has positioned itself as a differentiated care provider. Community pharmacies are vital, accessible healthcare destinations, providing care tailored to the community they serve. I'm continually inspired by the creativity and tenacity these community pharmacists exhibit, and I'm proud of Sincora's partnership with these market leaders. In closing, and before I hand it over to Jim, as I near the end of my first year as CEO, I'll remind you we are focused on four drivers that will strengthen our execution. Digital transformation, talent and culture, productivity, and prioritizing growth-oriented investments. We're focused on Sincora's digital transformation, using data and advanced analytics to accelerate operational excellence and enhance both the customer and team member experience. We're committed to developing our team members, ensuring Sincora is a place where -in-class talent come to grow their careers and furthering our purpose-driven culture. We've elevated our concentration and productivity, equipping us to identify ongoing capability and process improvements. And finally, our commitment to leading now and in the future means we prioritize investments in strategic growth-oriented areas. As evidenced by our continued investment in technology and capabilities for our customers, our acquisition of RCA, and our investment with a pathway to full ownership and one oncology. This also means that we continually evaluate the areas which are less strategically aligned where we should de-emphasize investment. To close, I want to again thank the Sincora team members. It's due to their expertise, efficient execution of our strategy, and dedication to our purpose that Jim and I are able to once again report such strong results. With that, I will turn the call over to Jim for an in-depth review of our third quarter results and our updated fiscal 2025 guidance. Jim?